BridgeBio Pharma, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €2.35B +30.2% €900.97M +68.5% 38.3% +0.087 pp N/A N/A
    (estimated) €1.81B +60.6% €534.84M -5,312.4% 29.6% +0.30 pp €631.35M +349.1% 34.9% +0.22 pp
    (estimated) €1.13B +63.5% -€10.26M -96.9% -0.9% +0.47 pp €140.59M -167.5% 12.5% +0.43 pp
    (estimated) €688.50M +72.0% -€331.17M -42.3% -48.1% +0.95 pp -€208.44M -5.0% -30.3% +0.25 pp
    (estimated) €400.32M +111.5% -€573.95M +25.6% -143.4% +0.98 pp -€219.45M -50.5% -54.8% +1.8 pp
    €189.27M +2,285.3% -€456.98M -16.7% -241.4% +67 pp -€443.36M -1.3% -234.2% +54 pp
    €7.94M -88.0% -€548.62M +30.2% -6,913.9% -63 pp -€449.01M +27.4% -5,658.5% -51 pp
    €66.23M +11.4% -€421.33M -22.7% -636.2% +2.8 pp -€352.42M -8.1% -532.1% +1.1 pp
    €59.46M +745.1% -€545.29M +32.1% -917.0% +49 pp -€383.56M +14.7% -645.0% +41 pp
    €7.04M -79.7% -€412.76M +85.8% -5,866.5% -52 pp -€334.52M +57.9% -4,754.5% -41 pp
    €34.60M +∞% -€222.14M +99.2% -642.1% -6.4 pp -€211.91M +109.7% -612.5% -6.1 pp
    €0.00 +NaN% -€111.52M +327.8% N/A -€101.04M +196.0% N/A
    €0.00 -€26.07M N/A -€34.14M N/A

    Notifications